ES2729111T3 - Método para la preparación de adyuvante de hidroxifosfato de aluminio - Google Patents

Método para la preparación de adyuvante de hidroxifosfato de aluminio Download PDF

Info

Publication number
ES2729111T3
ES2729111T3 ES12851733T ES12851733T ES2729111T3 ES 2729111 T3 ES2729111 T3 ES 2729111T3 ES 12851733 T ES12851733 T ES 12851733T ES 12851733 T ES12851733 T ES 12851733T ES 2729111 T3 ES2729111 T3 ES 2729111T3
Authority
ES
Spain
Prior art keywords
aluminum
phosphate
solution
buffer
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12851733T
Other languages
English (en)
Spanish (es)
Inventor
David Thiriot
Patrick Ahl
Jayme Cannon
Gabriel Lobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2729111T3 publication Critical patent/ES2729111T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/36Aluminium phosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES12851733T 2011-11-23 2012-11-19 Método para la preparación de adyuvante de hidroxifosfato de aluminio Active ES2729111T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563213P 2011-11-23 2011-11-23
PCT/US2012/065741 WO2013078102A1 (en) 2011-11-23 2012-11-19 Method for preparation of aluminum hydroxyphosphate adjuvant

Publications (1)

Publication Number Publication Date
ES2729111T3 true ES2729111T3 (es) 2019-10-30

Family

ID=48470220

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12851733T Active ES2729111T3 (es) 2011-11-23 2012-11-19 Método para la preparación de adyuvante de hidroxifosfato de aluminio

Country Status (6)

Country Link
US (1) US9573811B2 (cg-RX-API-DMAC10.html)
EP (1) EP2782594B1 (cg-RX-API-DMAC10.html)
KR (1) KR102032002B1 (cg-RX-API-DMAC10.html)
ES (1) ES2729111T3 (cg-RX-API-DMAC10.html)
IN (1) IN2014CN03391A (cg-RX-API-DMAC10.html)
WO (1) WO2013078102A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2989187C (en) * 2015-06-12 2025-05-27 Biological E Limited PROCESS FOR PREPARING AN ALUMINUM PHOSPHATE GEL FOR APPLICATION IN VACCINE FORMULATIONS
EP3528827A4 (en) 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
JP2021501144A (ja) * 2017-10-25 2021-01-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. アジュバントワクチン
BR112020015308A8 (pt) 2018-01-29 2023-02-07 Merck Sharp & Dohme Proteínas f de rsv estabilizadas e usos das mesmas
EP3556728A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
EP3798185A1 (en) * 2018-05-23 2021-03-31 The Research Foundation For Microbial Diseases Of Osaka University Aluminum phosphate compound
CA3112837A1 (en) * 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
WO2020207472A1 (zh) 2019-04-11 2020-10-15 厦门万泰沧海生物技术有限公司 唑来膦酸锌微纳米颗粒佐剂的制备及作为疫苗佐剂的用途
US12419951B2 (en) 2019-05-30 2025-09-23 Xiamen University Preparation of zinc risedronate micro/nano adjuvant and use thereof as vaccine adjuvant
CN113666404B (zh) * 2021-09-23 2023-07-28 北京智飞绿竹生物制药有限公司 一种适合规模化生产的高浓度纳米级氢氧化铝佐剂配制方法
KR20230047827A (ko) * 2021-10-01 2023-04-10 에스케이바이오사이언스(주) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
WO2024205322A1 (ko) * 2023-03-31 2024-10-03 에스케이바이오사이언스(주) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
WO2024233425A2 (en) 2023-05-08 2024-11-14 Merck Sharp & Dohme Llc Polynucleotides encoding norovirus vp1 antigens and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2181426B1 (cg-RX-API-DMAC10.html) 1972-04-06 1974-12-20 Pasteur Institut
US4016252A (en) 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
US8540955B2 (en) * 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
US8574589B2 (en) * 2009-05-11 2013-11-05 Novartis Ag Antigen purification process for pertactin antigen
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition

Also Published As

Publication number Publication date
US20140314653A1 (en) 2014-10-23
EP2782594A4 (en) 2015-07-29
US9573811B2 (en) 2017-02-21
EP2782594B1 (en) 2019-04-17
KR20140100530A (ko) 2014-08-14
EP2782594A1 (en) 2014-10-01
KR102032002B1 (ko) 2019-10-14
WO2013078102A1 (en) 2013-05-30
IN2014CN03391A (cg-RX-API-DMAC10.html) 2015-07-03

Similar Documents

Publication Publication Date Title
ES2729111T3 (es) Método para la preparación de adyuvante de hidroxifosfato de aluminio
ES2650740T3 (es) Composición de vacuna con unas nanopartículas de hidróxido de aluminio
ES2559060T3 (es) Composición de un conjugado multivalente de polisacárido neumocócico-proteína
ES2393182T3 (es) Disposición de cámaras de interacción y contrapresión para microfluidización
ES2634699T3 (es) Métodos para preparar composiciones nanocristalinas usando acústica enfocada
EP3062900A1 (en) Drying techniques for microfluidic and other systems
ES3025099T3 (en) Apparatus and method for mixing small liquid volumes, and use of the apparatus
JP7795235B2 (ja) Al-Mn複合ナノ結晶及びその製造方法と使用
BR112020001051A2 (pt) fabricação contínua de conjugados de medicamentos com molécula de orientação.
CN104968336A (zh) 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物
US20110008450A1 (en) Slow Release Compositions
CN202168952U (zh) 一种全自动无菌配药设备
CN106430141A (zh) 纳米锶羟基磷灰石的制备方法
BR112020001058A2 (pt) remoção de medicamento dissociado após acoplamento de conjugado a anticorpo e medicamento
ES2862379T3 (es) Método para la preparación de gel de fosfato de aluminio para su aplicación en formulaciones de vacuna
CN112295476A (zh) 静态微混合芯片装置、磷酸铝佐剂的制备方法及其应用
BR112017026816B1 (pt) Processo para a preparação de gel de fosfato de alumínio
CN117815383A (zh) 一种亚微米至纳米级粒径可调氢氧化铝佐剂的制备方法
JP2024119170A (ja) 医薬組成物、医薬組成物の製造方法および医薬組成物の製造装置
EA042612B1 (ru) Вакцинная композиция и способ ее получения
CN115209980B (zh) 用于保持溶液均质性的摇动平台
de São João Continuous Synthesis of Hydroxyapatite Nanoparticles in a Planar Oscillatory Flow Reactor: Effect of Surfactant Concentration
Connell Silica nanoparticles as adjuvants for novel vaccines: a combined immunological, simulation and physical characterisation study
CN103432132B (zh) 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法
HK40116872A (zh) 用於混合小液体体积的设备和方法以及该设备的用途